MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/hon.2769

Медицинская библиотека · Hematological oncology · 2020

Impaired virus-specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib.

Rumi Elisa, Sant'Antonio Emanuela, Cavalloni Chiara, Comolli Giuditta, Ferretti Virginia Valeria, Cassaniti Irene, Pietra Daniela, Trotti Chiara, Ciboddo Michele, Furione Milena, Vanni Daniele, Casetti Ilaria Carola, Favaron Cristina, Baldanti Fausto, Arcaini Luca, Cazzola Mario

СтатьяПеревод в очереди

Аннотация

Ruxolitinib is effective in myeloproliferative neoplasms (MPN) but can cause reactivation of silent infections. We aimed at evaluating viral load and T-cell responses to human cytomegalovirus (HCMV) and Epstein-Barr virus (EBV) in a cohort of 25 MPN patients treated with ruxolitinib. EBV-DNA and HCMV-DNA were quantified monthly using real-time polimerase chain reaction (PCR) on peripheral blood samples, and T-cell subsets were analyzed by flowcytometry. HCMV and EBV-directed T-cell responses were evaluated using the IFN-γ ELISPOT assay. Most patients had CD4+ and/or CD8+ T-cells below the normal range; these reductions were related to the duration of ruxolitinib treatment. In fact, reduced T-lymphocytes' subsets were found in 93% of patients treated for ≥5 years and in 45% of those treated for <5 years (P = .021). The former also had lower median numbers of CD4+ and CD8+ cells. Subclinical reactivation of EBV and HCMV occurred in 76% and 8% of patients. We observed a trend to an inverse relationship between EBV and CMV-specific CD4+ and CD8+ T-cell responses and viral load, and a trend to an inverse correlation with ruxolitinib dose. Therefore, our data suggest that the ruxolitinib treatment may interfere with immunosurveillance against EBV and HCMV.

Для цитирования: Rumi Elisa, Sant'Antonio Emanuela, Cavalloni Chiara, Comolli Giuditta, Ferretti Virginia Valeria, Cassaniti Irene, Pietra Daniela, Trotti Chiara, Ciboddo Michele, Furione Milena, Vanni Daniele, Casetti Ilaria Carola, Favaron Cristina, Baldanti Fausto, Arcaini Luca, Cazzola Mario. Impaired virus-specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib.. Hematological oncology. 2020. DOI: 10.1002/hon.2769.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.